SBC 014

Drug Profile

SBC 014

Alternative Names: AES-014; AVI-014; SBC-014

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator Synageva BioPharma
  • Class Granulocyte colony-stimulating factors; Proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neutropenia

Most Recent Events

  • 04 Nov 2010 Synageva BioPharma receives 12 grants under the US Government's Qualifying Therapeutic Discovery Project Programme
  • 30 Sep 2008 SBC 014 is available for licensing and/or co-development in the USA (http://www.synageva.com)
  • 30 Nov 2005 This programme is still in active development - (BIO-Europe-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top